Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-06-28

Tempus AI, Inc.

Tempus AI combines genomic diagnostics, clinician workflow software, and de-identified data analytics for providers and life-science customers.

ai enterprise healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A Diagnostics Flywheel Seeking Software Economics

The upside case is a transition from precision-testing vendor to regulated data and workflow utility. The hurdle is proving that new assays, evidence products, and AI workflows translate into durable cash generation rather than just more volume.

Analysis

Thesis

Tempus can grow faster than a normal diagnostics company because each test can feed a governed data asset, better models, and clinician or biopharma workflows; if it converts that flywheel into recurring higher-value contracts while capturing assay pricing uplift, equity value can roughly triple by 2031 without needing pure-software economics.

Last Economy Alignment

Tempus benefits as AI makes its governed data, regulated assays, and embedded workflows more valuable, but reimbursement, FDA timing, and data-rights rules still cap value capture.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.7x (from 5 most recent analyses)

Reasoning

The upside does not require Tempus to become a pure software company. It requires the business mix to keep shifting from lab volume toward better-priced assays, data products, evidence programs, and workflow surfaces that are harder to replace. If that happens, investors can value it as more than a diagnostics vendor but still below the very best software or MRD leaders.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is economic conversion, not product existence. Tempus has real demand, real data assets, and credible product breadth, but upside still passes through reimbursement, FDA timing, privacy permissioning, and proving that workflow and evidence products become durable budget-line revenue rather than helpful add-ons.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

June 25, 2026 rare-cancer collaboration added dataset depth in angiosarcoma; strategically positive, near-term revenue impact is small.
No new payer, FDA, or cash-conversion disclosure appeared in the last 7-10 days, so the next real proof point remains Q2 execution.
Late-May to June product news is still being digested: Lens agent expansion, xH launch prep, and xT migration all support the mix-shift story but do not yet prove monetization.

Thesis update

No material thesis change; recent releases reinforce the same diagnostics-to-data-to-workflow compounding story.

Forecast update

A cleaner capital structure, clearer pricing-uplift path after assay approval, and firmer confidence in EBITDA progression modestly improve quality of the upside.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.56

They control a stream of clinically grounded data, regulated tests, and workflow tools used by doctors and drug companies, so AI makes their information asset more valuable over time. The risk is that reimbursement, regulation, or hospital software incumbents limit how much of that extra value they actually keep.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$66.53

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research